OKYO Pharma Limited announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 12,500 of the Company’s ADSs on NASDAQ at a price of US$1.32 per ADS at a price of £0.0165 each).
OKYO Pharma Today Announces Director Acquires Shares Read More »
Medigene AG, an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported financial results for the year ended December 31, 2022 and provided a corporate update.
Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update Read More »
Shanghai Junshi Biosciences Co., Ltd and Rxilient Biotech announced the collaboration on the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.
Health rewards have traditionally included limited offerings that not all members can access. Now, open-loop rewards offer more choices than ever.
How open-loop networks are changing health rewards as we know them Read More »
Ohio Attorney General David Yost filed suit on Monday against the payers’ PBMs, along with Prime Therapeutics, for allegedly sharing pricing information and driving up drug prices.
Ohio AG sues ‘modern gangsters’ Cigna, Humana for alleged PBM price fixing Read More »
Thierry Bernard, the CEO of Qiagen, succeeds Norman Schwartz, CEO of Bio-Rad Laboratories, in leading the diagnostics division of trade association AdvaMed.
Qiagen’s Thierry Bernard named chair of the AdvaMedDx board Read More »
Walgreens’ U.S. healthcare division, including VillageMD, recorded $1.6 billion in sales in the quarter, an increase of $1.1 billion from last year.
Walgreens healthcare division boosts retail giant’s second-quarter earnings Read More »
Monopar Therapeutics is dropping its lead candidate, Validive, after it failed to meet efficacy markers in Phase IIb/III trials for severe oral mucositis.
Monopar Drops Lead Candidate after Disappointing Phase III Analysis Read More »
Bristol Myers Squibb is expanding its strategic collaboration with German partner Evotec for eight more years to discover and develop treatments for neurodegenerative diseases.
Evotec Up for Potential $4B More in Lucrative BMS Partnership Read More »
Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and develop targeted radioligand therapies in oncology.
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B Read More »
